1 / 33

ID Case Conference

ID Case Conference. Yvonne L. Ballard, MD 30 January 2008. CC: Fatigue, Shortness of Breath 49yo CM had a URI 2-3 weeks PTA. Sx included rhinorrhea, cough, malaise. Sx lasted one week, and resolved. 4 days PTA, recurrent sx developed.

gavan
Download Presentation

ID Case Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ID Case Conference Yvonne L. Ballard, MD 30 January 2008

  2. CC: Fatigue, Shortness of Breath • 49yo CM had a URI 2-3 weeks PTA. Sx included rhinorrhea, cough, malaise. Sx lasted one week, and resolved. • 4 days PTA, recurrent sx developed. • 2 days PTA, pt presented to PCP, who performed a rapid flu test, which was positive. Pt treated with Tamiflu, which he started to take immediately. • Sx progressed, and pt called EMS for severe fatigue and difficulty breathing

  3. PMH: None PSurgHx: Appendectomy, age 23 All: NKDA Meds: Nicorette gum SocHx: Lives with wife in CH 4 healthy children Ages 7, 9, 14, 17 Installs closets Chewed tobacco Occ. Beer No illicits FamHx: Mom, dec, Pancreatic CA Dad, alive, healthy Brother, alive, healthy Brother, alive, Colon CA

  4. Physical Exam • T 36.0, P 130s, BP 157/73, RR 33 • WD, WN ill man; intubated, sedated • NCAT, Pupils dilated, minimally reactive • Tachycardic, Reg rhythm, no m/g/r • BS coarse bilaterally, diffuse • Abd soft, NT, ND, NABS • Skin: diffuse maculopapular rash on head, trunk, and extremities • Ext: no c/c/e. Cool extremities

  5. 117 91 60 57 4.4 13 6.8 11.9 192 5.4 240 75 4.3 34.1 Labs • D-dimer 3397 • Fibrinogen 857 • AT III activity 49% • BNP 33,187 • CK 551, MB 24, Trop (–) • PT 35, PTT 53, INR 2.6 • Lactate 7.3 • ABG 6.93/66/44/58% • Etoh Screen Negative 4.5 1.3 8.1

  6. Micro Data • Urine Culture - Negative • HIV ELISA - Negative • RPR - NR • RMSF Serologies - Negative • CMV PCR - Negative • Skin Lesion HSV 1 and 2 PCR - Negative • EBV Serologies – Indicate previous exposure

  7. Discussion…

  8. Streptococcus pyogenes

  9. Hospital Course • Intubated in the ED • Started on Vanc, Zosyn, Levaquin • Levophed, Vasopressin, Phenylephrine • Bicarb gtt, IVF boluses • Three central lines placed • Multiple modes of ventilation failed • Worsening CXR • Propofol gtt • PEA Arrest…Successful code • Family consented for ECMO

  10. Hospital Course, cont. • Pt desats to 40s while en route to SICU • Prep for ECMO begins • Pt goes into Asystole • Resuscitation unsuccessful • Pronounced dead at 2:01 am, after 20 minute code

  11. Micro Data • Blood Culture, 4/4 bottles positive: • Streptococcus pyogenes (Group A Strep) • Induced sputum – Group A Strep • Right Lung Biopsy – Group A Strep • Right Lung Biopsy – Viral Cx Negative • Right Lung Biopsy – CMV PCR Negative

  12. Micro Data • Group A Strep Sensitivity Testing • Penicillin G (MIC 0.032) • Vancomycin (MIC 1) • Levofloxacin (MIC 0.5) • Erythromycin (sens) • Clindamycin (sens)

  13. Group A Streptococcus • Aerobic gram + coccus pairs and chains • Catalase negative • Beta-hemolytic on blood agar • Growth inhibited by bacitracin

  14. GAS Disease Manifestations

  15. Virulence Factors • M protein • Filamentous protein on cell membrane; has antiphagocytic properties • Types 1, 3, 12, and 28 most common in shock • Pts with decreased serum antibodies to M prot more susceptible to invasive infections • Exotoxins • Pyrogenic exotoxins A, B, and C; SSA, MF • Cause cytotoxicity, pyrogenicity, and enhances lethal effects of endotoxins

  16. Streptococcus pyogenes • Clinical presentations: • Pharyngitis, Sinusitis, Otitis Media • Skin and soft tissue infections • Impetigo, Erysipelas, Localized cellulitis • Invasive Disease • Bacteremia • Necrotizing Fasciitis, Gangrenous Myositis • Pneumonia • Toxic Shock Syndrome

  17. Diagnosis of STSS • Isolation of GAS from normally sterile site • AND Hypotension • PLUS evidence of organ failure (at least 2) • Renal failure • Coagulopathy • Liver involvement • ARDS • Soft tissue necrosis • Erythematous macular rash

  18. The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States, 2000-2004 • Data collection from CDC and ABCs • Population of 29.7 million persons over 10 US cities • San Francisco, Denver, Atlanta, Baltimore, Portland, Albany, Rochester, urban Tennessee, Minnesota, New Mexico, Conneticut • January 1, 2000 – December 31, 2004 • Invasive GAS = isolation of GAS from a normally sterile site or from a wound specimen obtained from a patient with nec fasc or STSS CID 2007; 45: 853-62

  19. 5400 cases of invasive GAS • Avg annual incidence = 3.5 cases per 100,000 persons CID 2007; 45: 853-62

  20. Clinical Presentation • Cutaneous or soft tissue infection (36%) • Primary Bacteremia (29%) • Pneumonia (15%) • GAS isolated from • Blood specimens (77%) • Joint Fluid (8%) • Surgical Specimens (6%) • Peritoneal fluid (2%) • Pleural fluid (2%) CID 2007; 45: 853-62

  21. CID 2007; 45: 853-62

  22. CID 2007; 45: 853-62

  23. Case Fatality Rates • Overall, CFR was 13.7% • Projections of US population estimate that 8950 – 11,500 invasive GAS infections occur annually, with 1050 – 1850 deaths • Predictors of Death • Increasing Age • Residence in Nursing Home • Presence of a Specific Disease Syndrome • Emm type (1, 3, 12) • Underlying condition CID 2007; 45: 853-62

  24. Morbidity and Mortality of Patients with Invasive Group A Streptococcal Infections Admitted to the ICU • Chart review of all cases of invasive GAS admitted to ICUs in all Ontario, Toronto b/w Jan 1992 and June 2002 • 62 total patients • 64% with skin/soft tissue infections • 20% with pneumonia • 68% had positive blood cultures • 50% with chronic disease • Overall mortality 40% • Directly correlated with APACHE II scores and with the number of organ failures • 55% had STSS: Mortality rate = 68% Chest 2006; 130; 1679-1686

  25. Treatment • Hemodynamic Support • Surgical Therapy • Empiric Antibiotics • Clindamycin PLUS: • A carbapenem OR a PCN plus beta-lactamase inhibitor • IVIG (1 gm/kg day one, then 0.5gm/kg days two and three)

  26. Limitations in treatment • PCN/Beta-lactamase • Studies suggest PCN failure with large organsim burden • PBPs decrease in the stationary phase of bacterial growth in vitro • IVIG • Used as an adjunct to antibiotics • Able to neutralize superantigens and facilitates opsonization of streptococci • Inadequate evidence to support its use

  27. Post-Influenza Pneumonia • Most common complication of influenza • Most frequent in patients with underlying chronic conditions • CV or Pulmonary Disease • DM, Renal dz, Hemoglobinopathy • Immunosuppressed • Residents of chronic care facilities • Primary Influenza Pneumonia vs. Secondary Bacterial Pneumonia

  28. Secondary Bacterial Pneumonia • Accounts for ~25% of influenza-associated deaths • Influenza causes decrease in size of cells and loss of cilia in epithelium lining the trachea and bronchus • S. pneumo most common organism (~48%) • S. aureus second most common (19%) • H. flu also implicated • Typically, a relapse of symptoms after some degree of improvement • ? Role of Oseltamivir Curr Med Res Opin. 2007 Dec;23(12):2961-70

  29. Have A Great Day!

More Related